{"id":1182799,"date":"2026-09-02T16:59:12","date_gmt":"2026-09-02T16:59:12","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/1182799\/"},"modified":"2026-09-02T16:59:12","modified_gmt":"2026-09-02T16:59:12","slug":"mounjaros-label-expands-type-1-diabetes-on-the-rise-testosterone-and-afib","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/1182799\/","title":{"rendered":"Mounjaro’s Label Expands; Type 1 Diabetes on the Rise; Testosterone and Afib"},"content":{"rendered":"

The FDA expanded the indication for tirzepatide (Mounjaro) to include reducing the risk of major adverse cardiovascular events<\/a> in high-risk adults with type 2 diabetes, Eli Lilly announced.<\/p>\n

Global type 1 diabetes prevalence is projected to rise 29% by 2049<\/a>, jumping from 9.4 million cases in 2025 to 12.1 million, according to data from the upcoming European Association for the Study of Diabetes meeting.<\/p>\n

In high metabolic risk pregnancies, metformin was linked to increased gestational age at delivery<\/a> but failed to reduce gestational diabetes, a patient-level meta-analysis found. (NEJM Evidence)<\/p>\n

Investigational multi-agonists amycretin and retatrutide appeared to yield even greater levels of weight loss<\/a> than approved anti-obesity medications, according to a systematic review of randomized trials. (Annals of Internal Medicine)<\/p>\n

People are turning to an unregulated gray market<\/a> to source retatrutide ahead of its official approval. (The Guardian)<\/p>\n

CVS and Walgreens have each filled roughly 100,000 prescriptions<\/a> for $50-a-month obesity medications under Medicare’s Bridge program. (NPR)<\/p>\n

Cardiovascular-kidney-metabolic syndrome was associated with higher risks of major blinding eye diseases<\/a>, including cataracts, glaucoma, and age-related macular degeneration, U.K. Biobank data showed. (Eye)<\/p>\n

New Mexico state funds will continue to cover gender-affirming care for minors<\/a> despite federal cuts to Medicaid and CHIP coverage. (The Guardian)<\/p>\n

An updated review returned mixed evidence about the relationship between testosterone and atrial fibrillation<\/a>. (Journal of the Endocrine Society)<\/p>\n

In adults with type 2 diabetes recovering from dialysis-requiring acute kidney injury, starting an SGLT2 inhibitor within 30 days of hospital discharge was linked with fewer adverse kidney events<\/a>. (JAMA Network Open)<\/p>\n

Roughly 14% of large employers said they already dropped or plan to drop coverage of GLP-1 drugs<\/a> next year, according to a survey from the Business Group on Health. (Reuters via AOL)<\/p>\n

Persistent use of tirzepatide (Zepbound) for weight loss in adults over 55 years was associated with lower long-term healthcare costs<\/a> in a U.S. cohort study, driven in part by fewer inpatient and emergency department visits. (Diabetes, Obesity and Metabolism)<\/p>\n","protected":false},"excerpt":{"rendered":"The FDA expanded the indication for tirzepatide (Mounjaro) to include reducing the risk of major adverse cardiovascular events…\n","protected":false},"author":2,"featured_media":1182800,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[4315],"tags":[30114,967,62902,105,56026,4326,16,15],"class_list":["post-1182799","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-cardio","tag-diabetes","tag-gestational-diabetes","tag-health","tag-macular-degeneration","tag-medication","tag-uk","tag-united-kingdom"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/117202515680101219","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/1182799","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=1182799"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/1182799\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/1182800"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=1182799"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=1182799"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=1182799"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}